Passage Bio initiated overweight at Raymond James; expects a de-risking event this year
Passage Bio (PASG) is trading~3.4% higherin the post-market after Raymond James started the coverage of the stock with an overweight…
Seeking Alpha
AGF Management Limited’s (AGFMF) CEO Kevin McCreadie on Q2 2021 Results – Earnings Call Transcript
AGF Management Limited (OTCPK:AGFMF) Q2 2021 Earnings Conference Call June 30, 2021 11:00 AM ETCompany ParticipantsAdrian Basaraba…
Deciphera doses first patient in early-stage DCC-3116 cancer trial
Deciphera Pharmaceuticals (DCPH) announces that it has dosed the first patient in the company’s early-stage trial ofDCC-3116…
Vor Biopharma: Targeted Therapies For Transplants
Vor has a lead asset entering phase 1 clinical trials for AML that has the potential to become the standard of care for stem…
NorthWest Healthcare Properties REIT: Enjoy Dividends, Don’t Expect Growth
NorthWest Healthcare Properties does remain an income stock and one which we find has a safe dividend, despite our dislike of…
Atossa Therapeutics: Hope Springs Eternal
After a blistering June rally, we see a temporary top here probably back to around the $4 level. Implied volatility remains significantly…
Seneca Foods: Still Undervalued
Seneca Foods (SENEA, SENEB): Market has an overly pessimistic outlook about the company, but I think the stock is a buy and can…
OppFi The Next Upstart
OppFi boasts +20% YoY growth, 100% ’15-20′ Revenue CAGR. TAM: 60 million Americans who have no access to credit.
A Low Valuation, High Growth Target: ANI Pharmaceuticals
ANI Pharmaceuticals is something of a forgotten name, after several years of stock losses and slack operating results. Strong…
Atlas: Much Higher Earnings Already Aboard
Recent disclosures and news flow suggest analyst estimates for ATCO are very low and will need to re-rate much higher providing…